Guler HP - Search Results

1

The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus.

Garcia-Soria G, Gonzalez-Galvez G, Argoud GM, Gerstman M, Littlejohn TW 3rd, Schwartz SL, O'Farrell AM, Li X, Cherrington JM, Bennett C, Guler HP. Garcia-Soria G, et al. Among authors: guler hp. Diabetes Obes Metab. 2008 Apr;10(4):293-300. doi: 10.1111/j.1463-1326.2008.00868.x. Diabetes Obes Metab. 2008. PMID: 18333888 Clinical Trial.

2

Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial.

Pattzi HM, Pitale S, Alpizar M, Bennett C, O'Farrell AM, Li J, Cherrington JM, Guler HP; PHX1149-PROT202 Study Group. Pattzi HM, et al. Among authors: guler hp. Diabetes Obes Metab. 2010 Apr;12(4):348-55. doi: 10.1111/j.1463-1326.2010.01195.x. Diabetes Obes Metab. 2010. PMID: 20380656 Clinical Trial.

3

Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design.

Hotho DM, de Bruijne J, O'Farrell AM, Boyea T, Li J, Bracken M, Li X, Campbell D, Guler HP, Weegink CJ, Schinkel J, Molenkamp R, van de Wetering de Rooij J, van Vliet A, Janssen HL, de Knegt RJ, Reesink HW. Hotho DM, et al. Among authors: guler hp. Antivir Ther. 2012;17(2):365-75. doi: 10.3851/IMP1989. Epub 2011 Nov 30. Antivir Ther. 2012. PMID: 22293533 Clinical Trial.

4

Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients.

Li J, Klemm K, O'Farrell AM, Guler HP, Cherrington JM, Schwartz S, Boyea T. Li J, et al. Among authors: guler hp. Curr Med Res Opin. 2010 Aug;26(8):2003-10. doi: 10.1185/03007995.2010.491266. Curr Med Res Opin. 2010. PMID: 20583949 Clinical Trial.

5

Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.

O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP. O'Farrell AM, et al. Among authors: guler hp. Clin Ther. 2007 Aug;29(8):1692-705. doi: 10.1016/j.clinthera.2007.08.005. Clin Ther. 2007. PMID: 17919550 Clinical Trial.

6

Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study.

Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB, Bray GA, Roberts WG, Heyman ER, Stambler N, Heshka S, Vicary C, Guler HP. Ettinger MP, et al. Among authors: guler hp. JAMA. 2003 Apr 9;289(14):1826-32. doi: 10.1001/jama.289.14.1826. JAMA. 2003. PMID: 12684362 Clinical Trial.

7

Insulin-like growth factor-1 lowers protein oxidation in patients with thermal injury.

Cioffi WG, Gore DC, Rue LW 3rd, Carrougher G, Guler HP, McManus WF, Pruitt BA Jr. Cioffi WG, et al. Among authors: guler hp. Ann Surg. 1994 Sep;220(3):310-6; discussion 316-9. doi: 10.1097/00000658-199409000-00007. Ann Surg. 1994. PMID: 8092898 Free PMC article.

8

Clinical uses of insulin-like growth factor I.

Bondy CA, Underwood LE, Clemmons DR, Guler HP, Bach MA, Skarulis M. Bondy CA, et al. Among authors: guler hp. Ann Intern Med. 1994 Apr 1;120(7):593-601. doi: 10.7326/0003-4819-120-7-199404010-00011. Ann Intern Med. 1994. PMID: 8116999 Review.

9

Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients.

Jabri N, Schalch DS, Schwartz SL, Fischer JS, Kipnes MS, Radnik BJ, Turman NJ, Marcsisin VS, Guler HP. Jabri N, et al. Among authors: guler hp. Diabetes. 1994 Mar;43(3):369-74. doi: 10.2337/diab.43.3.369. Diabetes. 1994. PMID: 8314009

10

Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus.

Schalch DS, Turman NJ, Marcsisin VS, Heffernan M, Guler HP. Schalch DS, et al. Among authors: guler hp. J Clin Endocrinol Metab. 1993 Dec;77(6):1563-8. doi: 10.1210/jcem.77.6.8263142. J Clin Endocrinol Metab. 1993. PMID: 8263142

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page